BBAS3:BMFBOVESPABanco do Brasil S.A. Analysis
Data as of 2026-03-11 - not real-time
R$25.14
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Banco do Brasil trades at R$25.14, roughly half of its DCF‑derived fair value of R$48.75, indicating a sizable discount. The stock’s price‑to‑earnings ratio of 10.5 is well below the industry average of 17.3, and its price‑to‑book of 0.76 underscores the undervalued status. Despite an 8% year‑over‑year revenue contraction, the bank maintains a solid operating margin of 23% and a profit margin of 15.5%. Forward earnings per share are projected at R$5.38, cutting the forward PE to 4.7, which signals improving earnings visibility. The dividend yield of 1.12% is supported by a low payout ratio of 20%, and the company holds ample cash of R$24.4 bn, suggesting sustainability. Analyst consensus remains neutral with a “hold” rating, reflecting cautious optimism amid modest growth prospects.
Technically, the price sits just above the 50‑day SMA (R$24.16) but below the 20‑day SMA (R$25.96), placing it in a narrow consolidation zone. The MACD histogram is negative and the signal line is bearish, while the RSI at 48 indicates neither overbought nor oversold conditions. Current support at R$24.24 and resistance at R$27.81 provide a defined range, and decreasing volume suggests limited short‑term momentum. Volatility remains high at 31% over the past 30 days, yet the beta of 0.21 points to low systematic risk relative to the market. Recent news highlights a profit rebound and a confirmed dividend distribution, reinforcing the earnings upside hinted by the fundamentals. Combined, these factors point to a modest upside potential of about 7% while keeping downside risk contained.
Technically, the price sits just above the 50‑day SMA (R$24.16) but below the 20‑day SMA (R$25.96), placing it in a narrow consolidation zone. The MACD histogram is negative and the signal line is bearish, while the RSI at 48 indicates neither overbought nor oversold conditions. Current support at R$24.24 and resistance at R$27.81 provide a defined range, and decreasing volume suggests limited short‑term momentum. Volatility remains high at 31% over the past 30 days, yet the beta of 0.21 points to low systematic risk relative to the market. Recent news highlights a profit rebound and a confirmed dividend distribution, reinforcing the earnings upside hinted by the fundamentals. Combined, these factors point to a modest upside potential of about 7% while keeping downside risk contained.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- price below fair value
- support level intact
- negative MACD suggests caution
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- undervalued multiples
- sustainable dividend
- profit rebound expectations
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- state‑backed stability
- low beta and systematic risk
- consistent cash generation
Key Metrics & Analysis
Financial Health
Revenue Growth-8.00%
Profit Margin15.54%
P/E Ratio10.5
ROE8.75%
ROA0.69%
P/B Ratio0.8
Op. Cash FlowR$135.0B
Industry P/E17.3
Technical Analysis
TrendBullish
RSI47.8
SupportR$24.24
ResistanceR$27.81
MA 20R$25.96
MA 50R$24.16
MA 200R$22.09
MACDBearish
VolumeDecreasing
Fear & Greed Index76.57
Valuation
Fair ValueR$48.75
Target PriceR$26.94
Upside/Downside7.15%
GradeUndervalued
TypeValue
Dividend Yield1.12%
Risk Assessment
Beta0.21
Volatility31.24%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.